Ozempic und Bauchspeicheldrüse: Ernährung, die das Risiko senkt

Is there a diet that lowers pancreatitis risk on Ozempic?

For Ozempic, we found no study that tested a low-fat plan, a fluid target or an alcohol limit against pancreatitis. The label's pancreatitis section deals with symptoms and what to do if the condition is suspected, not with food choices.

What the Ozempic label says

The Ozempic label states that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists including Ozempic. It tells prescribers to observe patients for signs and symptoms, which may include persistent or severe abdominal pain sometimes radiating to the back, with or without nausea or vomiting. If pancreatitis is suspected, the label says to discontinue Ozempic and initiate appropriate management [1].

Pancreatitis is not among the label's contraindications. Those are a personal or family history of medullary thyroid carcinoma or MEN 2, and a prior serious hypersensitivity reaction to semaglutide or an excipient [1].

How often pancreatitis appeared in the trials

A meta-analysis of 21 randomised trials covering 99,599 patients found no difference in pancreatitis between GLP-1 receptor agonists and control [2]. A review of real-world studies in people with type 2 diabetes or obesity reported no clear increase in severe events such as pancreatitis [3].

The related warning is gallbladder disease

The Ozempic label also warns about gallbladder disease. If gallstones or gallbladder inflammation are suspected, the label calls for gallbladder studies [1]. A review of semaglutide safety concluded that it increases the risk of biliary disease, specifically cholelithiasis [4].

Fluid loss and the kidneys

The label's separate fluid warning concerns the kidneys, not the pancreas. It describes acute kidney injury from volume depletion, mostly in people who had gastrointestinal reactions causing dehydration such as nausea, vomiting or diarrhea, and says to monitor renal function in patients reporting those reactions, especially during dose initiation and escalation [1].